Francisco J Esteva

List of Publications by Year in Descending Order

37 papers	1,825 citations	20 h-index	38 g-index
38 ext. papers	2,158 ext. citations	5.8 avg, IF	4.34 L-index

#	Paper	IF	Citations
37	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. *Clinical Cancer Research*, **2021**,	12.9	1
36	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 7388-7395	12.9	2
35	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. *Clinical Breast Cancer*, **2019**, 19, 268-277.e1	3	6
34	Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. *Breast Cancer Research and Treatment*, **2019**, 176, 687-696	4.4	7
33	Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. *Breast Cancer Research and Treatment*, **2019**, 173, 329-341	4.4	22
32	Trastuzumab-Resistant HER2 Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. *Molecular Cancer Therapeutics*, **2018**, 17, 921-930	6.1	7
31	High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. *International Journal of Cancer*, **2018**, 143, 3027-3034	7.5	30
30	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2) advanced breast cancer (ABC): Results from MONALEESA-3.. *Journal of Clinical Oncology*, **2018**, 36, 1000-1000	2.2	12
29	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 2804-2807	2.2	59
28	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 2736-2740	2.2	103
27	Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. *Oncotarget*, **2018**, 9, 12868-12878	3.3	32
26	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. *Scientific Reports*, **2017**, 7, 41960	4.9	42
25	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	23
24	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. *Lancet Oncology, The*, **2017**, 18, 917-928	21.7	62
23	Clinical utility of gene-expression signatures in early stage breast cancer. *Nature Reviews Clinical Oncology*, **2017**, 14, 595-610	19.4	127
22	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS1124-TPS1124	2.2	3
21	DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. *Oncotarget*, **2017**, 8, 77207-77218	3.3	20

20	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. *Clinical Breast Cancer*, **2016**, 16, 113-22.e1	3	43
19	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.. *Journal of Clinical Oncology*, **2016**, 34, TPS624-TPS624	2.2	10
18	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. *Molecular Oncology*, **2015**, 9, 586-600	7.9	23
17	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. *British Journal of Cancer*, **2015**, 113, 1003-9	8.7	23
16	Circulating tumor cell analysis in metastatic triple-negative breast cancers. *Clinical Cancer Research*, **2015**, 21, 1098-105	12.9	33
15	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e117-25	7.1	10
14	Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis. *Clinical Advances in Hematology and Oncology*, **2015**, 13, 25-31	0.6	3
13	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, **2014**, 32, 2100-8	2.2	129
12	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. *Journal of Clinical Oncology*, **2014**, 32, 2078-99	2.2	270
11	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. *Cancer*, **2014**, 120, 1932-8	6.4	33
10	Genome-based risk prediction for early stage breast cancer. *Oncologist*, **2014**, 19, 1019-27	5.7	4
9	Gene signature-guided dasatinib therapy in metastatic breast cancer. *Clinical Cancer Research*, **2014** , 20, 5265-71	12.9	20
8	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. *Oncotarget*, **2014**, 5, 9864-76	3.3	156
7	Detection of metastases in breast cancer: Is whole body PET/MR better than PET/CT?. *Journal of Clinical Oncology*, **2014**, 32, 15-15	2.2	
6	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer*, **2012**, 118, 2603-14	6.4	220
5	Residual risk of breast cancer recurrence 5 years after adjuvant therapy. *Journal of the National Cancer Institute*, **2008**, 100, 1179-83	9.7	245
4	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. *Oncology*, **2005**, 19, 4	1.8	2
3	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. *Oncology*, **2005**, 19, 5-16	1.8	7

2	The current status of docetaxel for metastatic breast cancer. *Oncology*, **2002**, 16, 17-26	1.8	6
1	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. *Cancer Chemotherapy and Pharmacology*, **2000**, 46, 382-6	3.5	30